Drug Trial Radar · NCT05104853
Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis
Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Jan 25, 2022
Primary completion
Jan 30, 2026
Study completion Jan 30, 2026
Sponsor
- Lead sponsor
- COUR Pharmaceutical Development Company, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.
Conditions
- Primary Biliary Cholangitis
Interventions
CNP-104Drug
CNP-104 is comprised of PDC-E2 peptide dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~1 μg of PDC-E2 peptide per mg of PLGA particles.
PlaceboDrug
CNP-104 Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: through Study Completion, an average of 720 Days
- Laboratory safety assessments (hematology, serum chemistry, coagulation panel, urinalysis).Time frame: through Study Completion, an average of 720 Days
- Serum Cytokines (TNF-α, IL-4, IL-6, IL-10, IL-1β, MCP-1, MIP-1α, IFN-γ)Time frame: through CNP-Dosing Period, an average of 15 Days
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Southern California Research Center
Coronado, California
OM Research
Lancaster, California
University of California Davis Health
Sacramento, California
Peak Gastroenterology Associates
Colorado Springs, Colorado
Yale School of Medicine
New Haven, Connecticut
University of Florida - Hepatology Research
Gainesville, Florida
Mayo Clinic Florida
Jacksonville, Florida
Florida Research Institute
Lakewood Rch, Florida
GI PROS Research
Naples, Florida
Cleveland Clinic - Florida
Weston, Florida
Digestive Healthcare of Georgia
Atlanta, Georgia
University of Chicago Medical Center
Chicago, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Henry Ford Health System
Novi, Michigan
Washington University School of Medicine in St. Louis
St Louis, Missouri
Montefiore Medical Center
The Bronx, New York
Duke University Medical Center
Durham, North Carolina
Texas Liver Institute
San Antonio, Texas
University of Virginia
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.